EF Hutton Reiterates Buy on Century Therapeutics, Maintains $16 Price Target
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Tony Butler has reiterated a 'Buy' rating on Century Therapeutics (NASDAQ:IPSC) and maintained a price target of $16.
August 10, 2023 | 8:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton has reiterated a 'Buy' rating on Century Therapeutics and maintained a price target of $16.
The reiteration of a 'Buy' rating by EF Hutton, a well-respected analyst, is a positive signal for Century Therapeutics. The maintained price target of $16 indicates that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100